Biggest News Aggregation in the World
๐Ÿ“ฐ Allo News

Page 7 - Allo News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Allo. Real-time updates on events, politics, business and more.

JPMorgan Chase & Co. Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its target price cut by JPMorgan Chase & Co. from $11.00 to $9.00 in a research report sent to investors on Monday morning, Marketbeat.com reports. They currently have an overweight rating on the stock. ALLO has been the subject of a number of other research reports. Oppenheimer reaffirmed […]
Stephen Mayo Metlife Investment Management Alphacrest Capital Management Blackrock Inc Allogene Therapeutics Inc Jpmorgan Chase Co
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have given a buy recommendation […]
Stephen Mayo Great West Life Assurance Co Proshare Advisors Ensign Peak Advisors Inc Mitsubishi Ufj Allogene Therapeutics Inc

HC Wainwright Weighs in on Allogene Therapeutics, Inc.'s Q3 2023 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Investment analysts at HC Wainwright upped their Q3 2023 earnings per share estimates for shares of Allogene Therapeutics in a report issued on Monday, August 7th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.48) for the quarter, up […]
Stephen Mayo Stifel Nicolaus Allogene Therapeutics Company Profile Allogene Therapeutics Inc Ef Hutton Acquisition Co Centaurus Financial Inc

William Blair Analysts Lift Earnings Estimates for Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Investment analysts at William Blair boosted their Q3 2023 earnings estimates for Allogene Therapeutics in a research note issued on Thursday, August 3rd. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($0.53) for the quarter, up from their prior […]
William Blair Stifel Nicolaus Allogene Therapeutics Inc Ensign Peak Advisors Inc Proshare Advisors Allogene Therapeutics Company Profile

Allogene Therapeutics (NASDAQ:ALLO) Reaches New 12-Month Low at $4.27

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.27 and last traded at $4.31, with a volume of 1199577 shares trading hands. The stock had previously closed at $4.59. Analyst Upgrades and Downgrades ALLO has been the topic […]
Stifel Nicolaus Allogene Therapeutics Company Profile Ef Hutton Acquisition Co Millennium Management Allogene Therapeutics Inc Jpmorgan Chase Co

Allogene Therapeutics (NASDAQ:ALLO) Given New $18.00 Price Target at Truist Financial

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target decreased by Truist Financial from $20.00 to $18.00 in a research report released on Wednesday, FlyOnTheWall reports. A number of other equities analysts also recently commented on ALLO. EF Hutton Acquisition Co. I reaffirmed a buy rating and set a $15.00 price objective on shares […]
Sanfordc Bernstein Stifel Nicolaus William Blair Proshare Advisors Great West Life Assurance Co Ensign Peak Advisors Inc
Source: wkrb13.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science